Nisa Investment Advisors LLC Has $1.34 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM

Nisa Investment Advisors LLC boosted its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 956.9% during the 3rd quarter, Holdings Channel.com reports. The fund owned 13,254 shares of the company’s stock after purchasing an additional 12,000 shares during the period. Nisa Investment Advisors LLC’s holdings in Rhythm Pharmaceuticals were worth $1,339,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Farther Finance Advisors LLC increased its stake in shares of Rhythm Pharmaceuticals by 1,110.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock worth $35,000 after purchasing an additional 322 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in Rhythm Pharmaceuticals by 65.9% in the second quarter. Osaic Holdings Inc. now owns 979 shares of the company’s stock worth $62,000 after purchasing an additional 389 shares in the last quarter. State of Wyoming bought a new stake in Rhythm Pharmaceuticals in the second quarter worth $67,000. Mirae Asset Global Investments Co. Ltd. increased its position in Rhythm Pharmaceuticals by 16.2% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,458 shares of the company’s stock worth $155,000 after buying an additional 342 shares during the last quarter. Finally, CWM LLC raised its holdings in Rhythm Pharmaceuticals by 19.6% during the second quarter. CWM LLC now owns 3,091 shares of the company’s stock valued at $195,000 after buying an additional 507 shares in the last quarter.

Insider Activity

In other news, insider Joseph Shulman sold 9,748 shares of the business’s stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $115.24, for a total transaction of $1,123,359.52. Following the transaction, the insider owned 8,509 shares in the company, valued at approximately $980,577.16. The trade was a 53.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Pamela J. Cramer sold 3,350 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $111.00, for a total transaction of $371,850.00. Following the transaction, the insider directly owned 20,814 shares of the company’s stock, valued at $2,310,354. This represents a 13.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 15,913 shares of company stock worth $1,818,963. Insiders own 6.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on RYTM shares. JMP Securities upped their price target on Rhythm Pharmaceuticals from $135.00 to $142.00 and gave the stock a “market outperform” rating in a research note on Thursday, September 25th. HC Wainwright upped their target price on Rhythm Pharmaceuticals from $110.00 to $123.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Morgan Stanley reissued an “overweight” rating and issued a $150.00 price target on shares of Rhythm Pharmaceuticals in a research report on Thursday, December 11th. Canaccord Genuity Group boosted their price objective on shares of Rhythm Pharmaceuticals from $114.00 to $141.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Finally, Guggenheim raised their target price on shares of Rhythm Pharmaceuticals from $120.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $130.00.

Rhythm Pharmaceuticals Stock Up 5.1%

Shares of RYTM stock opened at $113.34 on Thursday. Rhythm Pharmaceuticals, Inc. has a 12 month low of $45.90 and a 12 month high of $122.20. The firm has a market cap of $7.56 billion, a PE ratio of -36.56 and a beta of 2.00. The stock has a 50 day moving average of $105.70 and a 200-day moving average of $99.45.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.10). The company had revenue of $51.30 million during the quarter, compared to analyst estimates of $50.71 million. Rhythm Pharmaceuticals had a negative return on equity of 433.21% and a negative net margin of 110.32%. As a group, equities analysts predict that Rhythm Pharmaceuticals, Inc. will post -4.32 EPS for the current fiscal year.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.